Drugs Similar to Bremelanotide (Vyleesi) and Flibanserin (Addyi)

FDA-Approved (Same Indication)

Closely Related by Mechanism

1. Melanocortin Receptor Pathway (same as Bremelanotide)

• Melanotan II - the synthetic peptide precursor to bremelanotide; bremelanotide is a cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH). Melanotan II was studied as a tanning agent and libido enhancer but never approved due to adverse effects (uncontrolled erections, nausea). Bremelanotide was derived from it with a better safety profile.
• PT-141 - another name for bremelanotide itself (its investigational name). Some compounding pharmacies still supply it under this designation for off-label use in men with HSDD.

2. Serotonin-Modulating Agents (same pathway as Flibanserin)

• Buspirone - a 5-HT1A partial agonist (same receptor target as flibanserin) used off-label for HSDD. It has shown benefit in some trials, particularly when combined with testosterone. It is generally well-tolerated with an anxiolytic profile.
• Bupropion (Wellbutrin SR/XL) - dopamine and norepinephrine reuptake inhibitor; also used off-label. Studies in premenopausal women showed improvements in sexual arousal, orgasm completion, and sexual satisfaction. It is also useful in patients whose HSDD is SSRI-induced, since SSRIs suppress dopamine/NE tone. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Off-Label Hormonal Agents (Clinically Used)

3. Testosterone

• Transdermal testosterone (compounded gels/patches) is the most evidence-backed off-label option, particularly in postmenopausal women. It targets the androgenic drive underlying sexual desire.
• The ISSWSH Clinical Practice Guideline (2021) supports short-term testosterone in surgically or naturally postmenopausal women with HSDD at physiological premenopausal concentrations.
• Marketed as Intrinsa (testosterone patch) in Europe but was never FDA-approved in the US due to safety concerns.

4. Ospemifene (Osphena)

• A selective estrogen receptor modulator (SERM), FDA-approved for dyspareunia and vulvovaginal atrophy in postmenopausal women. Not for HSDD per se but addresses the pain/dryness component that can secondarily suppress desire. - Goodman & Gilman's Pharmacological Basis of Therapeutics

Investigational Combinations (Clinical Pipeline)

Mechanism-Based Comparison Summary

Pathway        Drug(s)
─────────────────────────────────────────────────────────
MC4R agonist   Bremelanotide, Melanotan II (precursor)
5-HT1A agonist Flibanserin, Buspirone
5-HT2A antag.  Flibanserin, Trazodone (in Lorexys)
DA/NE reuptake Bupropion (also in Lorexys)
Androgen       Testosterone (transdermal, intranasal)
SERM           Ospemifene (dyspareunia, not HSDD)
PDE5i          Sildenafil (in Librido; peripheral)

Key Clinical Points

• Flibanserin and bremelanotide remain the only FDA-approved options for HSDD in premenopausal women (as of 2025/2026).
• Bupropion and buspirone are the most commonly used off-label alternatives with reasonable evidence, especially when flibanserin is contraindicated (e.g., liver enzyme inducers/inhibitors conflict) or the patient is postmenopausal. (Barakeh et al., Ann Pharmacother 2025, PMID 38767282)
• Testosterone (transdermal) has the strongest off-label evidence in postmenopausal women specifically.
• Lorexys (bupropion + trazodone) is the most advanced investigational agent in the pipeline, noted in a 2025 review as "investigational therapies" alongside testosterone combinations. (How et al., Clin Obstet Gynecol 2025, PMID 39846877)
• For SSRI-induced sexual dysfunction, bupropion augmentation or switching is a practical strategy since it counteracts the serotonergic suppression of dopamine.